BROOK WHITAKER: Open Payments
NPI 1043783673 · BLOOMINGTON, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,239 in 79 payments from 18 companies in 2025. Trend: 2023 $2,546 · 2024 $671 · 2025 $1,239
Food & beverage: $1,239
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $201 |
| Novo Nordisk Inc | 17 | $190 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $169 |
| Novartis Pharmaceuticals Corporation | 5 | $100 |
| Verona Pharma, Inc. | 5 | $91 |
| PFIZER INC. | 4 | $79 |
| Axsome Therapeutics, Inc. | 3 | $61 |
| Astellas Pharma US Inc | 2 | $53 |
| Lilly USA, LLC | 3 | $46 |
| GlaxoSmithKline, LLC. | 2 | $38 |
Products named: CAPLYTA, QULIPTA, Ohtuvayre, LEQVIO, Ozempic, Auvelity, Wegovy, Veozah.
Industry payments across IN — which companies pay providers there.
